The Vaccine Group (TVG) and the Animal and Plant Health Agency (APHA) have been awarded £500,000 through Defra’s Farming Innovation Programme, delivered in partnership with Innovate UK, to advance TVG’s bovine respiratory syncytial virus (BRSV) vaccine programme.
BRSV is a major viral contributor to bovine respiratory disease, affecting cattle health, welfare and productivity worldwide.
The project, Feasibility Testing of a Novel Viral-Vectored BRSV Vaccine: Dose-Ranging Studies in Calves, will determine the minimum dose required to provide effective protection and assess whether this can be achieved following a single vaccination.
The award builds directly on data from a recently completed Innovate UK Smart-funded project. The earlier Smart project evaluated TVG’s bovine herpesvirus-4 (BoHV-4) vectored vaccine candidates in young calves with maternally derived antibodies. Vaccination prevented clinical disease, eliminated detectable infectious-virus shedding and resulted in minimal lung pathology following BRSV challenge: https://www.biorxiv.org/content/10.64898/2026.10.14.759068v1
Defining a lower effective dose and simpler vaccination schedule will be critical for further development towards a commercial product. For cattle producers in England, this could reduce vaccine and handling costs while making protection during the vulnerable early-life period easier to deliver.
As part of the project, Synergy Farm Health will conduct a questionnaire-based study in English cattle herds to quantify the incidence of bovine respiratory disease, its treatment and associated antibiotic use. The findings will provide a benchmark for assessing potential vaccine impact, inform antimicrobial-resistance policy and guide the design of future field trials that reflect the practical needs of cattle producers in England.
Of the £499,968 project funding, £271,468 has been awarded to TVG and £228,500 to APHA. Specialist subcontracted input will also be provided by Dr Geraldine Taylor at The Pirbright Institute.
Dr Jeremy Salt, Chief Executive Officer at TVG, said:
“Our earlier study demonstrated strong protection against BRSV in young calves. Remarkably, this was achieved in the presence of maternally derived antibodies, which can interfere with responses to vaccination during early life.
“This project represents the next important step: defining a practical vaccination regimen and generating the evidence needed to progress the programme towards commercial development.”